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AB0071 THERAPEUTIC EFFECTS OF BONE MARROW 
MESENCHYMAL STEM CELLS-DERIVED EXOSOMES 
ON OSTEOARTHRITIS
C. Dong1, Y. Liu1, A. Deng1, J. Ji1, W. Zheng1, Z. Gu1. 1Affiliated Hospital of 
Nantong University, Nantong, China
Background: Mesenchymal stem cells (MSCs) have shown chondroprotective 
effects in clinical models of osteoarthritis (OA)[1].
Objectives: The study aimed to investigate the therapeutic potential of exosomes 
from human bone marrow MSCs (BM-MSCs) in alleviating OA. 
Methods: The anterior cruciate ligament transection (ACLT) anddestabiliza-
tion of the medial meniscus (DMM) surgery were performed on the knee joints 
of a rat OA model, followed by intra-articular injection of BM-MSCs or their 
exosomes. The beneficial effects were evaluated by histological staining, OARSI 
scores and micro-CT. Furthermore, BM-MSCs-derived exosomes were admin-
istrated to primary human chondrocytes to observe the functional and molec-
ular alterations. In addition, lncRNA MEG3 were investigated in chondrocytes 
to explore the biological contents accounting for anti-OA effects of BM-MSCs- 
derived exosomes.
Results: Based on the observation in the rat OA model, both of BM-MSCs 
and BM-MSCs-derived exosomes alleviated cartilage destruction, reduced joint 
damage and restored the trabecular bone of OA rats. In addition, in vitro assays 
showed that BM-MSCs- exosomes could maintain the chondrocyte phenotype 
by increasing collagen type II synthesis and inhibiting IL-1β- induced senes-
cence and apoptosis. Furthermore, exosomal lncRNA MEG3 also reduced 
the senescence and apoptosis of chondrocytes induced by IL-1β, indicating 
that lncRNA MEG3 might partially account for the anti-OA effects of BM-MSC 
exosomes.
Conclusion: The exosomes from BM-MSCs exerted beneficial therapeutic 
effects on OA by reducing the senescence and apoptosis of chondrocytes, sug-
gesting that MSCs-derived exosomes might provide a candidate therapy for OA 
treatment.
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C. Sanchez1, K. Hemmer2, N. Kroemmelbein2, B. Seilheimer2, J. E. Dubuc3, 
C. Antoine4, Y. Henrotin1,4. 1University of Liège, Bone and Cartilage Research 
Unit, Liège, Belgium; 2Biologische Heilmittel Heel GmbH, Baden-Baden, 
Germany; 3Cliniques Universitaires Saint-Luc, Orthopedic Department, 
Brussels, Belgium; 4Artialis, Liège, Belgium
Background: HE-1100 is a multicomponent medicinal product. Initial preclinical 
data potentially suggest a preventive effect on cartilage degradation.
Objectives: This study aims to understand the mode of action of HE-1100 on OA 
chondrocytes in vitro.
Methods: Primary chondrocytes were obtained from 10 knee osteoarthritis (OA) 
patients undergoing knee replacement surgery. The cultures were treated with 
20% (v/v) HE-1100 or placebo. Samples were collected for subsequent RNA 
extraction using standard methods. The reads were generated with Illumina 
NextSeq5000 sequencer and aligned to the human reference genome (UCSC 
hg19) to generate the transcriptome. Differential expression analysis between 
HE-1100 and placebo was made in R using the DESeq2 package to identify the 
differentially expressed genes in the OA-associated regulatory pathways. The 
protein production of the selected genes was quantified by ELISA in 10 inde-
pendent human OA chondrocytes cultures.
Results: According to the DESeq2 analysis, HE-1100 significantly modified the 
expression of 13 genes in OA chondrocytes by at least 10% with an adjusted 
p-value < 0.05: EGR1 (+93%), FOS (+87%), NR4A1 (+43%), DUSP1 (+18%), 
ZFP36 (+18%), ZFP36L1 (+14%), NFKBIZ (+16%) and CYR61 (+14%) were 
upregulated and ATF7IP (-10%), TXNIP (-11%), C10orf10 (-12%), CLEC3A 
(-12%) and MMP13 (-18%) were downregulated after 24h HE-1100 treat-
ment. HE-1100 significantly increased (2.3 fold +/-1.2 after 24h, p=0.0444 and 
2.3-fold +/-1.0 after 72h, p=0.0239) the CYR61 protein production by human 
OA chondrocytes. After 72h, HE-1100 slightly but not significantly increased 
aggrecan production by 14 ± 19 % (p=0.1117) and significantly increased type 
II collagen pro-peptide production by 27 ± 20 % (p=0.0147). For both time 
points CYR61 production by OA chondrocytes was positively and significantly 
correlated with aggrecan (r=0.66, p=0.0004) and type II collagen pro-peptide 
(r=0.64, p=0.0008) production. In alginate beads culture, pro-MMP-13 was sig-
nificantly decreased by HE-1100 treated cultures from day 7 to day 14 (from 
-16 to -25 %, p<0.05) and from day 17 to 21 (-22 %, p=0.0331) in comparison 
to controls.
Conclusion: HE-1100 significantly modified the expression of DUSP1, 
C10orf10, ZFP36/L1 and CLEC3A, which are pathway mediators involved in 
MMP-13 expression and activation. Further, long-term (28 days) treatment with 
HE-1100 significantly reduced the production of pro-MMP-13, the inactive pre-
cursor of the metalloproteinase MMP-13 involved in type II collagen degrada-
tion. HE-1100 also promoted extracellular matrix formation probably through 
CYR61 production, a growth factor well correlated with type II collagen and 
aggrecan production. 
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Background: Boswellia serrata extract (BSE) and curcumin are used to relief 
symptoms in osteoarthritis (OA).
Objectives: This study aims to better understand the mode of action of these 
compounds on OA chondrocytes in vitro.
Methods: Therapeutic plasmatic concentrations of the different compo-
nents of BSE correspond to an in vitro range from 25 to 100 µg/ml of total 
BSE (100 µg/ml of BSE corresponds to 9.2 µM of 11-keto-β-boswellic acid 
(KBA), 5.2 µM of acetylKBA, 22 µM de αBA, 34 µM de βBA, 4.4 µM de 
acetylαBA and 13.2 acetyl βBA), and between 2 to 10 µM for bioavaibili-
ty-increased curcumin. BSE (5-100 µg/ml) and curcumin (0.04 to 4 µg/ml 
corresponding to 0.1 to 10 µM) were tested separately on primary chon-
drocytes from 3 OA patients. Lactate Deshydrogenase LDH, nitrite (NO
2
), 
interleukin (IL)-6 and Growth Differentiation Factor (GDF)15 were quanti-
fied in 72h-treated supernatant using enzyme activity, Griess reaction and 
ELISAs, respectively.
Results: No mortality was observed at the tested concentrations. BSE and 
curcumin both decreased concentration-dependently NO
2
 and IL-6 produc-
tion, and increased GDF15 production. For NO
2
 production, the decrease was 
observed from 0.2 µg/ml of curcumin and 10 µg/ml of BSE. For IL-6 production, 
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